Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials

BMJ Open
August 2017 – Volume 7 – 8
http://bmjopen.bmj.com/content/current

Oncology – Research
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials
Matti Lehtinen, Camilla Lagheden, Tapio Luostarinen, Tiina Eriksson, Dan Apter, Katja Harjula, Marjo Kuortti, Kari Natunen, Johanna Palmroth, Tiina Petäjä, Eero Pukkala, Mari Siitari-Mattila, Frank Struyf, Pekka Nieminen, Jorma Paavonen, Gary Dubin, Joakim Dillner
Conclusions: Ten years post vaccination the AS04-adjuvanted HPV-16/18 vaccine shows continued efficacy against CIN3+ irrespectively of HPV type. Vaccine efficacy was not observed in baseline HPV16 DNA positive subjects.